** Shares of drugmaker Bristol Myers Squibb BMY.N up 3.2% at $57.61

** Co says the U.S. FDA has accepted for review its marketing application seeking approval of the combination of BMY's Opdivo plus Yervoy as a potential first-line treatment option for patients with types of colorectal cancer

** The FDA is set to make a decision by June 23

** Opdivo plus Yervoy is already approved to treat cancers of the skin, lung, kidney, colon and esophagus

** BMY has rose ~10% in the last 12 months

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))